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Ras is a guanine nucleotide-binding protein that cycles between
inactive GDP-bound and active GTP-bound states to regulate a
diverse array of cellular processes, including cell growth, apoptosis,
and differentiation. The guanine nucleotide-bound state of Ras is
tightly maintained by regulatory factors to promote regulated
growth control. A class of regulatory molecules that lead to Ras
activation are guanine nucleotide exchange factors (GEFs). Ras
GEFs bind to Ras and facilitate GDP release, followed by GTP
incorporation and Ras activation. Nitric oxide (NO) has also been
shown to promote guanine nucleotide exchange (GNE) on Ras and
increase cellular Ras-GTP levels, but the process by which NO-
mediated GNE occurs is not clear. We initiated NMR structural and
biochemical studies to elucidate how nitrosylation of Ras might
lead to enhanced GNE. Surprisingly, our studies show that stable
S-nitrosylation of Ras at Cys-118, does not affect the structure of
Ras, its association with the Ras-binding domain of Raf (a down-
stream effector of Ras), or GNE rates relative to non-nitrosylated
Ras. We have found, however, that the actual chemical process of
nitrosylation, rather than the end-product of Ras S-nitrosylation,
accounts for the enhanced GNE that we have observed and that has
been previously observed by others.
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Nearly 20 years ago, nitric oxide (NO) was identified as avaso-relaxation factor and was found to mediate its effects
on smooth muscle by coordinating the heme moiety of guanylate
cyclase, leading to enhanced production of cGMP (1). It was
later shown that increased levels of cGMP modulate the function
of other physiological targets, such as protein kinases, phos-
phodiesterases, and ion channels, causing vaso-relaxation (as
reviewed in refs. 1–3). NO has also been shown to modulate
cGMP-independent pathways by modifying a multitude of cel-
lular biomolecules containing reactive metal centers, as well as
cysteine residues (4–6). Although NO is able to modulate the
activity of tyrosine kinases, serinethreonine kinases, guanosine
triphosphatases (GTPases), and phosphatases, the molecular
basis of NO modification and the subsequent effect on enzyme
activity are not completely understood. NO is generally believed
to exert its effects on biomolecules by direct modification of a
residue important for protein structure or enzymatic catalysis.
The Ras GTPase is a protein product of the most commonly
mutated oncogene in all of human cancer (ras), and has been
identified as a target for S-nitrosylation by NO (7). Ras is a
molecular switch that cycles between an inactive GDP-bound
state and an active GTP-bound state, to regulate a number of
cellular processes, including cell growth, differentiation and
apoptosis (for reviews, see refs. 8–10). In its oncogenic form, Ras
is populated in a GTP-bound state and is constitutively active.
The chronic activation of Ras leads to persistent activation of
downstream signaling cascades to promote cellular transforma-
tion. In normal tissues, however, regulatory proteins tightly
maintain the activity of Ras (as reviewed in refs. 11–13). These
regulatory proteins, termed guanine-nucleotide exchange fac-
tors (GEFs) and GTPase-activating proteins (GAPs), bind to
Ras and either facilitate GDP release followed by GTP incor-
poration and, therefore, Ras activation (GEFs), or enhance GTP
hydrolysis to GDP and, hence, Ras inactivation (GAPs). Several
lines of evidence show Ras to be modified and activated by NO
in vivo (7, 14, 15). First, Lander et al. (7) showed that human T
cells treated with NO gas contain an increased percentage of Ras
in the GTP-bound form. Additionally, in vitro experiments
showed that purified H-Ras exchanged guanine nucleotide more
rapidly in the presence of NO gas (7). It was later shown that
Cys-118 was the Ras residue modified by NO and that a C118S
Ras variant, while otherwise normal (16), cannot be S-
nitrosylated and does not respond to NO in vitro or in vivo (14).
Other in vivo studies have shown that activation of neuronal-NO
synthase (nNOS) in rodent primary cortical neuronal cultures, by
addition of N-methyl-D-aspartate (NMDA), populates Ras in its
active GTP-bound state (15). Moreover, the addition of NMDA
to nNOS-deficient (nNOS/) cultures does not lead to activa-
tion of Ras (15).
The observed enhancement of guanine nucleotide exchange
(GNE) on treatment with NO was attributed to a structural
change in Ras, resulting in a conformation that binds the guanine
nucleotide with lower affinity (7). This mechanism for NO action
was deduced by analogy to other systems where NO modification
results in either the perturbation of a catalytic residue or the
structural alteration of the modified protein. Inspection of the
Ras structure, however, provides little support for either of these
modes of NO action. Cys-118 is the most solvent-exposed
cysteine in Ras, decreasing the likelihood that side-chain mod-
ifications will induce significant structural perturbations. More-
over, even though Cys-118 is located in the NKXD guanine
nucleotide-binding motif, it occupies the hypervariable position
and does not form specific contacts with the guanine nucleotide
or any of the other residues in the guanine nucleotide-binding
pocket (17, 18). Additionally, mutation of Cys-118 to serine
results in a variant of Ras that does not differ significantly from
wild-type Ras in structure or GNE (16). The lack of involvement
of the Cys-118 side chain in guanine nucleotide coordination and
guanine nucleotide-binding site architecture makes it difficult to
understand how the addition of a nitroso group could alter the
guanine nucleotide-binding properties or the structure of Ras.
This paper was submitted directly (Track II) to the PNAS office.
Abbreviations: Cys-NO, S-nitroso-cysteine; GNE, guanine nucleotide exchange; GEF, GNE
factor; GS-NO, S-nitroso-glutathione; GTPase, guanosine triphosphatase; HSQC, hetero-
nuclear single quantum coherence; NOE, nuclear Overhauser enhancement; Raf-RBD,
Ras-binding domain of Raf-1; mSOS, murine Son of Sevenless GEF.
†Present address: National Institute of Environmental Health Sciences, Laboratory of
Structural Biology, 111 Alexander Drive, Mail Drop F0-04, Research Triangle Park, NC
27709.
‡Present address: Prodigene, Inc., 101 Gateway Boulevard, Suite 100, College Station, TX
77845.
¶To whom correspondence should be addressed. E-mail: campbesl@med.unc.edu.
6376–6381  PNAS  May 27, 2003  vol. 100  no. 11 www.pnas.orgcgidoi10.1073pnas.1037299100
To better define the effects of S-nitrosylation on Ras structure
and activity, we generated stably and stoichiometrically S-
nitrosylated Ras and used NMR structural and biochemical
studies to elucidate how NO activates Ras.
Materials and Methods
Chemicals and Reagents. All chemicals, unless otherwise noted,
were purchased from Sigma. [3H]GDP was purchased from
NEN.
Ras(1–166) Purification. Wild-type Ras(1–166) and Ras(1–
166)C118S were purified as described (19).
Determination of Nitroso Content. Nitroso contents were deter-
mined by the Saville assay essentially as described (20).
S-Nitrosylation of Ras. Equal volumes of 100 mM L-cysteine or
glutathione in 0.25 M HCl and 100 mM NaNO2 in dH2O were
mixed and incubated for 10 min at room temperature in the dark.
After incubation, reaction mixtures were diluted 4:1 with buffer
(20 mM Tris, pH 7.4l mM diethylenetriamine pentaacetic acid),
and the pH was adjusted to pH 7.4 with NaOH. After determi-
nation of nitroso content by using the Saville assay (20), the
nitroso donor S-nitroso-cysteine (Cys-NO) was added in 100-
fold excess to Ras in reaction buffer and incubated for 30 min at
room temperature in the dark. After removal of excess donor
with a PD-10 desalting column (Pharmacia), the recovered Ras
was assayed for nitroso content before being used in assays.
Mass Spectrometric Analysis. Measurements were made on a
Micromass Quattro LC (Altrincham, U.K.) triple quadrupole
mass spectrometer equipped with a pneumatically assisted elec-
trostatic ion source operating at atmospheric pressure and in a
positive ion mode. Samples were diluted with an equivolume of
acetonitrile containing 1% formic acid. Analyses were made by
loop injection into a stream of 50% aqueous acetonitrile flowing
at 10 lmin. Spectra were acquired in the multichannel analyzer
mode from mz 600–1,400 (scan time 5 s). The mass scale was
calibrated by using the multiply charged envelope of the horse
heart myoglobin (Mr 16951.48). The raw mass spectra were
transformed to a molecular mass scale by using a maximum
entropy-based method that uses the MEMSYS5 program (MaxEnt
Solutions, Cambridge, U.K.) and is part of the Micromass
MASSLYNX software suite. Transformation was performed from
800–1,400 mz by using a resolution of 1 atomic mass unit.
Ras-Binding Domain of Raf-1 (Raf-RBD) Binding Assay. Fluorescence
anisostropy measurements were conducted on a 2.5-ml sample of
0.5 M Ras-Mant-GDP, Ras-Mant-GMPPNP, S-nitrosylated
Ras-Mant-GDP, or S-nitrosylated Ras-Mant-GMPPNP in 20
mM Tris, 50 mM NaCl, 5 mM MgCl2 by using a Perkin–Elmer
LS50B spectrophotometer at 25°C. GST-tagged Raf-RBD frag-
ment (Raf-1 residues 50–131) was titrated into the Ras, and the
resulting increase in anisotropy was recorded as a function of
Raf-RBD concentration. Equilibrium dissociation constants,
KDs, were determined by fitting the data to a hyperbola (Y 
BmaxX(KD  X). In this equation, Y is the anisotropy value
normalized from 0 to 1, Bmax is the anisotropy value at saturation
(1 for normalized anisotropy values), X is the Raf-RBD con-
centration, and KD is the equilibrium dissociation constant.
GNE Assay. A 500-l sample of 5 M Ras(1–166), S-nitrosylated
Ras(1–166), or Ras(1–166)C118S in 20 mM Tris (pH 7.4), 50
mM NaCl, and 5 mM MgCl2, with either 500 M Cys-NO, 500
M S-nitroso-glutathione (GS-NO), 5 mM EDTA, 1 M mSOS
(murine Son of Sevenless), or buffer control, was prepared.
Assays were initiated by the addition of [3H]GDP, and aliquots
were removed at specific time points and spotted onto nitrocel-
lulose filters. The filters were then washed with a 2-ml reaction
buffer three times. Radioactivity was assayed in a Beckman-
Coulter scintillation counter, by using EcoScint fluid (Fisher).
NMR Structural Studies. NMR experiments were recorded on a
Varian Inova 600 (600 MHz) spectrometer at 25°C. 2D 1H–15N
heteronuclear single quantum coherence spectroscopy (HSQC)
experiments were performed with pulsed field gradient and
water flip-back methods described (21). HSQC experiments
were acquired with 1,024  128 complex data points and a
spectral width of 8,000 Hz for the 1H dimension and 1,709 Hz for
the 15N dimension. 15N-edited 3D nuclear Overhauser enhance-
ment (NOE) experiments were acquired with 1,024  48  32
complex data points with a mixing time of 120 ms. NMR data
were processed and analyzed by using the program FELIX V. 97.2
(Accelrys, San Diego).
Results
To investigate how treatment of Ras with NO leads to activation
of Ras, we conducted a series of structural and biochemical
studies on S-nitrosylated Ras. Structural studies were initiated by
preparing stably and stoichiometrically S-nitrosylated H-Ras.
Mass spectrometric analysis was used to characterize Ras-species
generated by Ras S-nitrosylation. Mass spectrometric results
described in Fig. 1 show that addition of Cys-NO to Ras(1–166)
produces a nearly complete, stoichiometric modification of Ras
by NO whereas the Ras(1–166)C118S variant is insensitive to
Cys-NO treatment. These results indicate that Ras is specifically
modified by NO, because the increase in mass of the Ras protein
on treatment with Cys-NO corresponds to the mass of an NO
moiety. Moreover, our results indicate that NO modification of
Ras is specific to residue Cys-118, because the mass of the
Ras(1–166)C118S variant is not altered by Cys-NO treatment.
This finding was later confirmed by NMR. These mass spectro-
metric results also eliminate the possibility that unanticipated
side-reactions or by-products of Cys-NO treatment induce Ras
modification.
After preparing S-nitrosylated Ras, we conducted NMR stud-
ies to evaluate whether the structure of S-nitrosylated Ras differs
from wild-type Ras. Both 2D 1H–15N HSQC and 3D 15N-edited
NOE data were acquired to elucidate whether chemical shift
andor structural differences can be detected between S-
nitrosylated Ras and unmodified Ras. A 1H–15N HSQC is a 2D
Fig. 1. Mass spectral data of Ras(1–166) and Ras(1–166)C118S before and
after treatment with Cys-NO. (Lower Left) Mass chromatogram representative
of Ras(1–166). The larger peak corresponds to Ras(1–166), whereas the smaller
peak corresponds to a loss of the N-terminal methionine and hence Ras(2–
166). (Upper Left) Mass chromatogram of Ras(1–166) after treatment with
Cys-NO. Note the gain of 30 mass units for both the Ras(1–166) and the
Ras(2–166). A small shoulder to the left of the S-nitrosylated Ras(1–166) peak
corresponds to a small population of unmodified Ras(1–166). The mass chro-
matograms in Right represent the Ras(1–166)C118S variant of Ras. The ap-
proximate 16 mass unit shift in molecular weight in the mass of Ras from Lower
Right relative to the mass of Ras as determined in Lower Left signifies the
C118S mutation. The Ras(1–166)C118S variant does not gain mass after expo-
sure to Cys-NO as can be seen in Upper Right.








NMR experiment that selects for protons attached to 15N nuclei
(22). The ability to selectively observe amide resonances pro-
vides a site-specific probe for every amino acid in the protein
except for proline, a spectral fingerprint of Ras. Comparison of
the chemical shift changes between the HSQC spectrum of
unmodified Ras and the spectrum of NO-labeled Ras show
minor chemical shift differences (Fig. 2) that are restricted to
residues proximal to Cys-118 in three-dimensional space (Fig. 3).
The small, localized chemical shift differences between NO-
modified and unmodified Ras indicate that Ras does not un-
dergo a large-scale structural perturbation on modification of
Cys-118 by NO. Although the limited chemical shift perturba-
tions in the HSQC spectra are unlikely to reflect significant
structural changes, the qualitative nature of the 1H–15N HSQC
perturbation map does not eliminate the possibility of local
conformational rearrangement occurring around Cys-118.
Therefore, we collected 3D 15N-edited NOESY data on NO-
modified Ras. This experiment detects through-space proton
dipoles coupled to amide protons and provides a measure of
inter-proton distances (23). We compared NOE spectra between
unmodified and S-nitrosylated Ras, and found only small and
local NOE differences (Fig. 4). As yet, it is not clear whether
these observed differences reflect any NO-induced structural
change in Ras, because most of the changes in the NOE
resonances near the site of nitrosylation (i.e., Cys-118 and
Ser-145) are likely due to shifts in the NOE resonances caused
by a modified chemical environment (R-SH to R-S-NO) rather
than an altered Ras structure. Overall, there are relatively few
differences in the NOE resonances in nitrosylated Ras relative
to non-nitrosylated Ras. The magnesium binding site in Ras, as
illustrated by the slices for Gly-13 and Lys-16, and the effector
binding region, as depicted by Asp-33, do not show NO-induced
changes in the NOE resonances. These results are consistent
with our HSQC results, indicating that no notable structural
perturbations occur in Ras on S-nitrosylation of Cys-118.
Although our data indicate that S-nitrosylation of Ras does
not significantly alter the structure of the protein, we conducted
studies to determine whether stable nitrosylation of Ras alters
binding interactions with the Ras binding domain of Raf (Raf-
RBD). These studies were initiated because of reports indicating
that nitrosylation of Ras leads to increased coimmunoprecipi-
tation of two of its effectors, the Raf kinase and phosphatidyl-
inositol 3-kinase (24, 25). However, it was not determined
whether the recruitment of effectors to Ras was mediated
through an increase in Ras-GTP levels or through an increase in
effector affinity that is independent of the guanine nucleotide
bound state.
Fig. 2. 1H–15N-HSQC of Ras(1–166) before and after treatment with Cys-NO.
NMR overlay of Ras alone (red) and S-nitrosylated Ras (green). The HN reso-
nances that overlay (yellow) indicate no differences in structure or chemical
environment. Most HN resonance shifts are small and correspond to residues
localized to the regions around residue Cys-118.
Fig. 3. The regions of Ras affected by S-nitrosylation. Model of Ras(1–166)-
GDP (PDB 1CRQ) displaying the nucleotide-binding pocket. The guanine
nucleotide is colored cyan. The amino acid residues that correspond to HN
resonances that showed differences in chemical shift between unmodified Ras
and S-nitrosylated Ras are highlighted in red.
Fig. 4. NOE slices of Ras-GDP and S-nitrosylated-Ras-GDP. 15N-edited 1H–1H-
NOE data were collected on non-nitrosylated and S-nitrosylated Ras-GDP. The
NOE data suggest only minor structural perturbation on nitrosylation. As
representative data, the 1H–1H-NOE slices for residues Cys-118 (15N plane 
111.4, unmodified Ras; 112.0, S-nitrosylated Ras), Ser-145 (15N plane  110.8
unmodified Ras; 110.4 S-nitrosylated Ras), Gly-13 (15N plane  111.8, unmod-
ified Ras; 111.8, S-nitrosylated Ras), Lys-16 (15N plane  123.6, unmodified Ras;
123.6, S-nitrosylated Ras), and Asp-33 (15N plane  125.8, unmodified Ras;
125.8, S-nitrosylated Ras) are shown. Note that, even though the D1 1H and D3
15N chemical shift values are altered by nitrosylation (for 118Cys and 145Ser), the
1H–1H NOE patterns (i.e., number and type of NOEs) are similar.
6378  www.pnas.orgcgidoi10.1073pnas.1037299100 Williams et al.
To differentiate between these two possibilities, we compared
the amount of unmodified Ras and S-nitrosylated Ras that was
associated with the Raf-RBD using a fluorescence based assay.
In this assay, Ras is labeled with a fluorescent analog of GDP
(Mant-GDP) or an analog of GTP (Mant-GMPPNP). GST-Raf-
RBD (50–131) is then titrated into the Ras sample, the change
in fluorescence anisotropy is measured, and the KDs are deter-
mined by fitting the data to a single saturated site. As demon-
strated in Fig. 5, there is no difference in the KD of Ras-
GMPPNP or S-nitrosylated-Ras-GMPPNP to the Raf-RBD.
These results are not surprising, because the residues in Ras
whose chemical shifts are affected by S-nitrosylation are far
removed from the effector domain (residues 30–40), the region
of Ras that interacts with the Raf-RBD (26). Moreover, our
NOE data indicate that stable nitrosylation of Ras does not
induce structural differences around the effector domain (Fig.
5). These results suggest that the previously observed increase in
association of Ras to Raf in the presence of nitrosylating agents
is likely a result of increased levels of Ras-GTP rather than
altered affinity of S-nitrosylated Ras for Raf.
Next, we assayed the effects of S-nitrosylation on the rate of
Ras GNE. These assays were conducted under two different
conditions. First, GNE assays were performed on stably modi-
fied S-nitrosylated Ras. Second, the assays were conducted as
described (7), where the nitrosylating agent (Cys-NO or GS-NO)
was added to Ras at the beginning of the nucleotide exchange
procedure to monitor the affects of the nitrosylation event on
GNE. As shown in Fig. 6, neither the intrinsic nor GEF-
stimulated GNE rate of Ras-GDP is altered by stable nitrosy-
lation of Ras. In particular, unmodified Ras and S-nitrosylated
Ras possess similar, slow intrinsic guanine nucleotide dissocia-
tion rates, whereas unmodified Ras and S-nitrosylated Ras
treated with the murine guanine-nucleotide exchange factor,
mSOS, demonstrate rapid [3H]GDP loss, but in an identical
fashion, indicating that the presence of an NO moiety on Cys-118
does not significantly affect either intrinsic or GEF-mediated
GNE. To control for the possibility that NO may directly affect
SOS activity, we pretreated SOS with NO and performed GNE
assays. Pretreatment of SOS with NO did not show any effect on
SOS-mediated Ras GNE (data not shown).
A different NO-mediated effect was observed when conducting
the GNE assay under the second condition, where GNE is moni-
tored immediately after the addition of nitrosylating agents. Al-
though the presence of an NO moiety on Cys-118 had little effect
on GNE, the introduction of the NO-donating reagents Cys-NO
and GS-NO both increased the rate of GNE (Fig. 7), suggesting that
the chemical process of S-nitrosylation at Cys-118 may account for
the GNE enhancement observed previously. The enhanced rate of
GNE in the presence of NO-donating reagents is Cys-118 depen-
Fig. 5. S-Nitrosylation of Ras does not alter its ability to recognize effectors.
In this assay, Ras was labeled with a fluorescent analog of either GDP (Mant-
GDP) or GTP (Mant-GMPPNP), and anisotropy measurements were made as a
function of Raf-RBD concentration. Little binding of the Raf-RBD is observed
when Ras is GDP bound (inactive form) to either non-nitrosylated Ras (E) or
S-nitrosylated Ras (ƒ). In contrast, when Ras is complexed with Mant-GMPPNP,
the Raf-RBD binds with a KD of 20 nM to both non-nitrosylated (F) and
S-nitrosylated Ras (). These values are consistent with preexisting litera-
ture (28).
Fig. 6. Stable S-nitrosylation does not affect intrinsic or GEF-mediated
guanine nucleotide dissociation. In this assay, Ras or S-nitrosylated Ras was
preloaded with [3H]GDP. The assay was initiated by adding either an excess of
nonradioactive GDP, or an excess of nonradioactive GDP and a catalytic
amount of SOS, and followed as a function of time. As radioactive nucleotide
dissociates from Ras, a corresponding loss of radioactivity is observed. The
intrinsic rate of guanine nucleotide dissociation for Ras () and S-nitrosylated
Ras (Œ) was comparable. Although addition of mSOS to both untreated and
S-nitrosylated Ras enhances the rate of guanine nucleotide dissociation, sim-
ilar enhancements were observed for both S-nitrosylated Ras (■ ) and un-
treated Ras (F).
Fig. 7. An NO donor enhances the rate of GNE. This exchange assay was
performed by adding [3H]GDP to either wild-type or C118S Ras, alone, or in the
presence of EDTA, Cys-NO, or GS-NO, and the incorporation of [3H]GDP was
monitored over time. The EDTA serves as a positive control by chelating the
magnesium from Ras so that guanine nucleotide affinity is decreased and
rapid dissociation and reassociation of the guanine nucleotide can occur. This
result is shown by the rapid incorporation of the radiolabeled guanine nu-
cleotide into EDTA-treated Ras (F). Ras in the absence of NO-donating re-
agents (■ ) shows very little guanine nucleotide incorporation during the time
course of the experiment, whereas Ras treated with NO-donating reagents
Cys-NO () or GS-NO (E) shows an increase in the GNE relative to Ras alone.
The C118S mutant Ras (Œ), which cannot be S-nitrosylated, is insensitive to
Cys-NO treatment.








dent (Fig. 7), because mutation of Cys-118 to Ser renders Ras
insensitive to NO-mediated GNE. C118S Ras exchanges guanine
nucleotide normally in the absence of NO, and the addition of
Cys-NO does not increase the rate of [3H]GDP incorporation. To
exclude the possibility that oxidation or degradation by-products of
Cys-NO contribute to the enhanced GNE observed in the presence
of Cys-NO, the assay was repeated in the presence of cysteine,
nitrite, and nitrate. None of these compounds produced an increase
in GNE (data not shown).
Discussion
It has been established that NO can modify Ras at Cys-118 and act
as a positive regulator of Ras signal transduction (7, 14, 15, 27–29).
To further elucidate how treatment of Ras with NO donating agents
leads to Ras activation in vivo, we conducted structural and
biochemical studies on S-nitrosylated Ras. Our mass spectrometric
and NMR analyses indicate that addition of Cys-NO to Ras
modifies only Cys-118, with S-nitrosylated Ras as the end-product
of Cys-NO treatment. No alternative sites of Ras modification by
NO or by-products of Cys-NO decomposition were detected under
the conditions used in this study. Treatment of Ras with NO-
donating agents has been previously shown to enhance Ras GNE
(7). Hence, we investigated the possibility that stable nitrosylation
of Cys-118 alters Ras structure and subsequently influences Ras
GNE. However, our studies revealed that stable S-nitrosylation of
Ras at Cys-118 does not cause any significant perturbations in the
secondary or tertiary structure of Ras, and does not influence Ras
GNE in the presence or absence of the Ras GEF, SOS. Cys-118 is
a solvent-exposed residue that makes no contacts with either the
guanine nucleotide substrate or other residues in Ras (17, 18);
therefore, a large-scale structural perturbation in Ras was neither
expected nor observed on S-nitrosylation of Cys-118. The site of
S-nitrosylation is removed from the effector binding region (30);
however, it was not clear whether more subtle structural alterations
in Ras resulting from S-nitrosylation might affect effector binding,
because previous studies indicated that Ras nitrosylation leads to
increased association of Ras to the Ras effectors Raf-1 and phos-
phatidylinositol-3 kinase (24, 25). However, the binding affinity of
the Raf-RBD to Ras was not influenced by stable nitrosylation of
Ras. Although our results indicate that neither Raf-RBD binding
nor SOS-mediated GNE of Ras is altered by stable S-nitrosylation
of Ras, we cannot exclude the possibility that other GEF(s),
GTPase-activating protein(s), or effectors may be specifically al-
tered in their abilities to recognize S-nitrosylated Ras relative to its
non-nitrosylated counterpart. However, our observations that sta-
ble S-nitrosylation of Ras does not affect the structure or biochem-
ical properties of Ras are consistent with previous studies of a Ras
C118S variant of Ras that behaves essentially like wild-type protein
except that it is not responsive to NO signaling (16).
Although the presence of an NO moiety on Cys-118 does not
affect Ras GNE, our results show that the introduction of
NO-donating reagents Cys-NO and GS-NO both increase the
rate of Ras GNE, indicating that the chemical process of Ras
nitrosylation accounts for the enhanced GNE in the presence of
NO reagents, observed previously. In the case of Cys-NO, the
affect seems to be specific because neither nitrite, nitrate, nor
cysteine promotes GNE exchange on Ras (data not shown).
Consistent with these observations, we have found that NO gas,
Cys-NO, and GS-NO can modify Ras through a radical mechanism,
where formation of a Ras-radical intermediate reduces the affinity
of Ras for its guanine nucleotide substrate, leading to enhanced
guanine nucleotide dissociation (J. Heo & S.L.C., unpublished
results). Whereas our structural and biochemical studies indicate
that the end-product of S-nitrosylation of Ras (Ras-S-NO) does not
alter Ras structure, GNE or Raf-RBD binding, the data set forth
in this paper indicate that an intermediate of the nitrosylation
reaction, rather than the R-S-NO end product, alters Ras structural
elements and biochemical properties.
In summary, our results indicate that the addition of NO-
donating reagents (Cys-NO and GS-NO) to Ras causes enhanced
Ras-GNE, consistent with earlier studies. However, results from
this work and our other studies indicate that it is the actual process
of S-nitrosylation, rather than the product of S-nitrosylation (Ras-
S-NO), that interferes with guanine nucleotide substrate binding,
resulting in enhanced guanine nucleotide dissociation (J. Heo &
S.L.C., unpublished results). Similar to the effects of GEFs and
certain Ras mutations, NO treatment of Ras can lead to enhanced
Ras GNE and up-regulation of Ras activity in vivo. However, it is
unclear how Ras is regulated by NO in vivo. NO is produced from
NOSs (2). NOSs are complex regulatory enzymes that can produce
either bursts of NO or constant levels of NO in response to the
needs of the cell (31). Ras can in turn be activated in response to
cellular conditions where NOS is stimulated and can transduce
signals through multiple pathways, leading to changes in cell
morphology, gene expression, and apoptosis. Moreover, in vivo
activation of Ras by NO may be co-regulated andor may involve
GEF proteins. One can imagine a scenario where GEF proteins
may act synergistically with NO to displace the guanine nucleotide
from Ras. It will be of interest to further elucidate details of the
reaction mechanism involving NO-mediated regulation of Ras
activity and how Ras is regulated by NO in vivo.
The effects of NO on GNE may not be unique to Ras. We
anticipate that other GTPases containing the NKCD motif, such
as Rap, many of the Rabs, and the prokaryotic forms of the
elongation factor EF-Tu (32–34), may share a similar sensitivity
to NO and display enhanced GNE and, hence, increased GTP
loading. Furthermore, other redox active agents may show
similar affects. The mechanisms by which NO and other reactive
oxygen and nitrogen species modulate the activities of Ras and
other GTPases warrant further investigation.
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